Author:
Johnston Mary E.,Brouwers Melissa C.,Browman George P.
Abstract
Objectives: To describe a methodology used to keep practice guidelines up to date and to summarize data collected during the first year of implementing this plan with a cancer practice guidelines program.Methods: The updating strategy includes regular searches of peer-reviewed literature and meeting proceedings, review and interpretation of new evidence, review and revision of clinical recommendations, and notification to practitioners and policy makers about new evidence and its impact on recommendations.Results: Eighty pieces of new evidence were found relating to seventeen of the twenty guidelines included in this study. On average, four pieces of new evidence were found per guideline, but there was considerable variation across the guidelines. Of the eighty pieces, nineteen contributed to modifications of clinical recommendations in six practice guidelines, whereas the remaining evidence served to support the original recommendations. None of the modifications led to changes that advised against original recommendations. MEDLINE, the Cochrane Library, and meeting proceedings yielded many pieces of evidence, whereas CancerLit and HealthStar did not contribute significantly to the overall yield. Furthermore, key pieces of evidence that led to modifications to the recommendations were often identified by members of the disease site groups before appearing in electronic databases.Conclusions: The updating process is resource intensive but yields important findings. In response to this evaluation, the updating protocol has been revised such that literature searches are conducted quarterly and the scope of sources searched routinely is restricted to MEDLINE, the Cochrane Library, and meeting proceedings.
Publisher
Cambridge University Press (CUP)
Reference49 articles.
1. Brundage MD , Crook JM , Lukka H , and the Genitourinary Cancer Disease Site Group.1998;Use of strontium89 in endocrine-refractory prostate cancer metastatic to bone.Cancer Prev Control.22:79 87.
2. Rusthoven J , Bramwell V , Stephenson B , and the Provincial Systemic Treatment Disease Site Group.Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer [recommendation]. Cancer Care Ontario Practice Guidelines Initiative Web site. Available at: http://hiru.mcmaster.ca/ccopgi/guidelines/sys/cpg12_2.html. Accessed: September 27, 2000.
3. Stöger H , Samonigg H , Krainer M, et al .1998;Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: A randomised study with two schedules of granulocyte-macrophage colony stimulating factor.Eur J Cancer.34:482 488.
4. Terrell JE , Fisher SG , Wolf GT , for the Veterans Affairs Laryngeal Cancer Study Group.1998;Long-term quality of life after treatment of laryngeal cancer.Arch Otol Head Neck Surg.124:964 971.
5. Browman GP , Levine MN , Mohide EA, et al .1995;The practice guidelines development cycle. A conceptual tool for practice guidelines development and implementation.J Clin Oncol.13:502 512.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献